|
NCOA6 |
nuclear receptor coactivator 6 |
- BMAL1:CLOCK,NPAS2 activates circadian expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Cytoprotection by HMOX1
- Heme signaling
- Formation of WDR5-containing histone-modifying complexes
- Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
|
|
|
NCOR2 |
nuclear receptor corepressor 2 |
- PPARA activates gene expression
- NOTCH1 Intracellular Domain Regulates Transcription
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Loss of MECP2 binding ability to the NCoR/SMRT complex
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- HCMV Early Events
- NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
- Cytoprotection by HMOX1
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
|
|
NEDD4 |
NEDD4 E3 ubiquitin protein ligase |
- ISG15 antiviral mechanism
- Downregulation of ERBB4 signaling
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
NELFB |
negative elongation factor complex member B |
- Formation of RNA Pol II elongation complex
- Formation of the Early Elongation Complex
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Pausing and recovery of Tat-mediated HIV elongation
- Abortive elongation of HIV-1 transcript in the absence of Tat
- Tat-mediated HIV elongation arrest and recovery
- Tat-mediated elongation of the HIV-1 transcript
- HIV elongation arrest and recovery
- Pausing and recovery of HIV elongation
- RNA Polymerase II Pre-transcription Events
- TP53 Regulates Transcription of DNA Repair Genes
- RNA Polymerase II Transcription Elongation
- NTRK3 as a dependence receptor
|
|
|
|
NFE2L1 |
NFE2 like bZIP transcription factor 1 |
|
- Dodecyldimethylamine N-oxide
|
|
|
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
- Neddylation
- Potential therapeutics for SARS
- Regulation of HMOX1 expression and activity
- Heme signaling
- KEAP1-NFE2L2 pathway
- KEAP1-NFE2L2 pathway
- Nuclear events mediated by NFE2L2
- GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
- NFE2L2 regulating TCA cycle genes
- NFE2L2 regulating inflammation associated genes
- NFE2L2 regulating anti-oxidant/detoxification enzymes
- NFE2L2 regulates pentose phosphate pathway genes
- NFE2L2 regulating tumorigenic genes
- NFE2L2 regulating MDR associated enzymes
- NFE2L2 regulating ER-stress associated genes
- Regulation of NFE2L2 gene expression
- Regulation of NFE2L2 gene expression
- Regulation of PD-L1(CD274) transcription
|
|
|
|
NFYA |
nuclear transcription factor Y subunit alpha |
- PPARA activates gene expression
- Activation of gene expression by SREBF (SREBP)
- Activation of gene expression by SREBF (SREBP)
- ATF4 activates genes in response to endoplasmic reticulum stress
- ATF6 (ATF6-alpha) activates chaperone genes
- ATF6 (ATF6-alpha) activates chaperone genes
- FOXO-mediated transcription of cell death genes
|
|
|
|
NFYC |
nuclear transcription factor Y subunit gamma |
- PPARA activates gene expression
- Activation of gene expression by SREBF (SREBP)
- Activation of gene expression by SREBF (SREBP)
- ATF4 activates genes in response to endoplasmic reticulum stress
- ATF6 (ATF6-alpha) activates chaperone genes
- ATF6 (ATF6-alpha) activates chaperone genes
- FOXO-mediated transcription of cell death genes
|
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
- Regulation of NPAS4 gene transcription
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
NR5A1 |
nuclear receptor subfamily 5 group A member 1 |
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Transcriptional regulation of pluripotent stem cells
- Transcriptional regulation of testis differentiation
|
- (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE
- Phosphatidyl ethanol
|
- Premature ovarian failure
- 46,XY disorders of sex development (Disorders of gonadal development), including: Gonadal agenesis; Complete and partial gonadal dysgenesis; Testis regression; Ovotesticular DSD
|
|
NRIP1 |
nuclear receptor interacting protein 1 |
- SUMOylation of transcription cofactors
- Estrogen-dependent gene expression
- NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
- NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis
- Heme signaling
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
- 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE
|
|
|
NTRK3 |
neurotrophic receptor tyrosine kinase 3 |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Receptor-type tyrosine-protein phosphatases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- NTF3 activates NTRK3 signaling
- NTF3 activates NTRK3 signaling
- Signaling by NTRK3 (TRKC)
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through PLCG1
- Activated NTRK3 signals through RAS
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- NTRK3 as a dependence receptor
|
- Entrectinib
- Fostamatinib
- Larotrectinib
- Pralsetinib
|
|
|
PACS1 |
phosphofurin acidic cluster sorting protein 1 |
- Nef mediated downregulation of MHC class I complex cell surface expression
|
|
|
|
PHOX2A |
paired like homeobox 2A |
|
|
- Congenital fibrosis of the extraocular muscles (CFEOM)
|
|
PIAS1 |
protein inhibitor of activated STAT 1 |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- SUMOylation of transcription cofactors
- SUMOylation of intracellular receptors
- SUMOylation of intracellular receptors
- SUMOylation of chromatin organization proteins
- Formation of Incision Complex in GG-NER
- Regulation of IFNG signaling
|
|
|
|
PIAS2 |
protein inhibitor of activated STAT 2 |
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
|
|
|
PIN1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
- ISG15 antiviral mechanism
- RHO GTPases Activate NADPH Oxidases
- Regulation of TP53 Activity through Phosphorylation
- PI5P Regulates TP53 Acetylation
- Negative regulators of DDX58/IFIH1 signaling
|
- Beta-(2-Naphthyl)-Alanine
- 3,6,9,12,15,18-HEXAOXAICOSANE
|
|
|
PML |
PML nuclear body scaffold |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Regulation of TP53 Activity through Acetylation
- Interferon gamma signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN localization
- HCMV Early Events
|
|
- Acute myeloid leukemia (AML)
|
|
POU1F1 |
POU class 1 homeobox 1 |
|
|
- Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Thyroid cancer
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Type II diabetes mellitus
|